LinJie Yang – Trademark Portfolio

Entity Type: 01

LinJie Yang holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 18 (Leather Goods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include SEERWAY and PAPARELA. The owner is based in Guangzhou.

NO.97 Yunxiang Road, Building 15

Tonghe Street, Baiyun District

Guangzhou 510000 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

PAPARELA
PAPARELA
Registered 2025
SEERWAY
SEERWAY
Registered 2025
MUFISH
MUFISH
Abandoned 2016

Trademark Classifications

LinJie Yang's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

18
Leather Goods (1 filing)

Leather and imitations of leather; animal skins, hides; trunks and travelling bags

Frequently Asked Questions

How many trademarks does LinJie Yang have?

LinJie Yang has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.

What trademark classes does LinJie Yang file in?

LinJie Yang files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 18 (Leather Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are LinJie Yang's most well-known trademarks?

LinJie Yang's registered trademark portfolio includes well-known marks such as SEERWAY and PAPARELA. These are among 2 currently registered trademarks in the portfolio.

What is LinJie Yang's trademark registration success rate?

LinJie Yang has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.